Atara Biotherapeutics has achieved significant regulatory milestones—including conditional marketing authorizations in Europe for its lead T-cell immunotherapy Ebvallo—while continuing to navigate ongoing FDA clinical evaluation pathways, regulatory reviews, and multi-phase trial protocols for its broader developmental pipeline in the United States.